Daiichi forecasts 3.9% sales drop; Impax posts 11% increase in sales;

@FiercePharma:  Dutch researchers are comparing GSK's Advair Diskus with a rival device in a study funded by $GSK. Item | Follow @FiercePharma

> Daiichi Sankyo shares dropped after the drugmaker lowered its sales forecast for the year ending March 2012, predicting a decline of 3.9% on the stronger yen. Article

> Impax Laboratories ($IPXL) posted street-beating profits of $17.2 million on revenue of $119.8 million, an 11% year-over-year increase. Story

> Contract manufacturer Lonza saw revenue growth suffer during the third quarter, thanks to the strength of the Swiss franc and high raw materials prices. Item

> Lupus organizations are lobbying the U.K.'s National Institute for Health and Clinical Excellence for coverage on the new drug Benlysta from Human Genome Sciences and GlaxoSmithKline ($GSK). Release

> Environmental and parent groups are pushing Johnson & Johnson ($JNJ) to remove potentially harmful chemicals from U.S. versions of its baby shampoo as it has in some other markets. News

Biotech News

@FierceBiotech: PathoGenetix raises $7.5M in second closing of series B financing for rapid bacterial identification system. Story | Follow @FierceBiotech

@JohnCFierce: Exelixis has always had problems with study designs; source of issue with BMS. Fight the FDA, though? Shares tank. Item | Follow @JohnCFierce

@RyanMFierce: U.K. trial aims to test use of agents to make tricky brain tumors glow to aid surgical removal. Makes sense. Report | Follow @RyanMFierce 

> Exelixis clashes with FDA over prostate cancer study, shares tank. Story

> NPS Pharma shares sink after cancers reported in patients on bowel drug. Report

> Report: Biotech VCs from Morgenthaler, ATV part ways with IT colleagues. Item

Biotech Research News

> Jackson Lab ready to start hiring for new genetics center. Item

> Caltech team designs a new and improved HIV antibody. Article

> Court ruling could derail ambitious stem cell program for synthetic blood. Report

> Investigators tout a new therapeutic approach to cardiovascular disease. News

Manufacturing News

> Ranking: Baxter, J&J lead green pharma companies. News

> Researchers tout big increase in heparin yield. Report

> KV Pharma, ex-CEO battle over recall responsibility. Item

> Closures a sign of Novartis minimizing production in Switzerland. Report

> Obama takes aim at drug shortages. News 

And Finally... A significant number of colon cancers could be caused by a bacteria, a new study finds. Article

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.